Abemaciclib-loaded ethylcellulose based nanosponges for sustained cytotoxicity against MCF-7 and MDA-MB-231 human breast cancer cells lines

• Main Authors: Md. Khalid Anwer (Author), Farhat Fatima (Author), Mohammed Muqtader Ahmed (Author), Mohammed F. Aldawsari (Author), Amer S. Alali (Author), Mohd Abul Kalam (Author), Aws Alshamsan (Author), Musaed Alkholief (Author), Abdul Malik (Author), Alanazi Az (Author), Ramadan Al-shdefat (Author)
• Format: Book
• Published: Elsevier, 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abemaciclib (AC) is a novel, orally available drug molecule approved for the treatment of breast cancer. Due to its low bioavailability, its administration frequency is two to three times a day that can decrease patient compliance. Sustained release formulation are needed for prolong the action and...